Drug Profile
BM-ca
Alternative Names: Anti-CD20 monoclonal antibody - BioMedicsLatest Information Update: 10 May 2016
Price :
$50
*
At a glance
- Originator BioMedics Japan
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors; CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma
Most Recent Events
- 10 May 2016 No recent reports on development identified- Phase-I for Non-Hodgkin's lymphoma in Japan (IV)